Precipio (PRPO) to Release Earnings on Wednesday

Precipio (NASDAQ:PRPO) is expected to issue its Q2 2026 results after the market closes on Wednesday, July 29th. Analysts expect Precipio to post earnings of ($2.00) per share and revenue of $1.6750 million for the quarter. Interested persons can find conference call details on the company’s upcoming Q2 2026 earning summary page for the latest details on the call scheduled for Wednesday, August 12, 2026 at 4:00 PM ET.

Precipio (NASDAQ:PRPO) last posted its quarterly earnings results on Thursday, May 14th. The biotechnology company reported ($0.81) EPS for the quarter. Precipio had a negative net margin of 3.57% and a negative return on equity of 6.73%. The firm had revenue of $6.71 million during the quarter.

Precipio Price Performance

Shares of PRPO stock opened at $22.92 on Tuesday. Precipio has a 12 month low of $13.80 and a 12 month high of $33.63. The company has a market capitalization of $41.03 million, a P/E ratio of -48.77 and a beta of 1.27. The stock has a 50 day moving average of $23.68 and a two-hundred day moving average of $25.18. The company has a current ratio of 1.56, a quick ratio of 1.33 and a debt-to-equity ratio of 0.05.

Analysts Set New Price Targets

A number of research analysts recently commented on the company. Weiss Ratings restated a “sell (d-)” rating on shares of Precipio in a research note on Friday, July 17th. Wall Street Zen downgraded shares of Precipio from a “buy” rating to a “hold” rating in a research note on Saturday, May 16th. One research analyst has rated the stock with a Sell rating, According to MarketBeat.com, Precipio presently has a consensus rating of “Sell”.

Institutional Investors Weigh In On Precipio

Several large investors have recently modified their holdings of the stock. Susquehanna International Group LLP bought a new position in shares of Precipio during the 3rd quarter worth approximately $194,000. Renaissance Technologies LLC grew its position in Precipio by 10.7% in the fourth quarter. Renaissance Technologies LLC now owns 14,500 shares of the biotechnology company’s stock valued at $333,000 after acquiring an additional 1,400 shares during the period. Finally, Geode Capital Management LLC raised its stake in Precipio by 5.1% during the fourth quarter. Geode Capital Management LLC now owns 16,388 shares of the biotechnology company’s stock worth $377,000 after acquiring an additional 789 shares in the last quarter. 10.45% of the stock is currently owned by institutional investors.

Precipio Company Profile

Precipio, Inc is a clinical-stage diagnostics and medical technology company focused on advancing the detection and management of hematologic diseases. The firm develops precision diagnostic solutions that integrate digital morphology, immunophenotyping, and molecular testing to improve the diagnosis of leukemia and related blood disorders. Precipio’s approach is designed to enhance the accuracy and speed of laboratory workflows, helping physicians tailor treatment strategies more effectively.

The company’s core offerings include an automated digital imaging and analysis platform that captures and classifies blood and bone marrow cell images at high throughput.